Longhorn Vaccines & Diagnostics an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations, will present scientific data at IDWeek 2019, which will be held in Washington, D.C. on October 2-6.
Updated pre-clinical data will be presented on Longhorn Vaccines & Diagnostics’ leading candidates for a universal influenza vaccine. The patented configuration combines multiple conserved regions on the influenza virus. Data will be presented demonstrating strong activity against influenza strains across both group 1 and 2. This approach builds on vaccine candidates that have recently entered the clinical stage that cross strains within groups but not across group. Clara Sei, Director of Microbiology & Immunology Laboratory Longhorn Vaccines & Diagnostics, will present the poster. Further details will be available on the date of presentation.
Presentation Details:
Title: Peptide Vaccines Utilizing Conserved Hemagglutinin, Neuraminidase, and Matrix Ectodomain Influenza Epitopes Demonstrate Functional Activity Against Group 1 and 2 Influenza Strains
Location: Walter E. Washington Convention Center, Exhibit Hall BC
Date: Saturday, October 5
Time: 12:15 pm ET – 1:30 pm ET
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines & Diagnostics is an innovative molecular tool, assay and vaccine development company focused on serving unmet critical needs in both developed and developing nations. Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA approved, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations and drug manufacturers improve the diagnosis and treatment of infectious diseases such as mycobacterium tuberculosis (TB) and Influenza. Unlike standard devices for collecting and transporting TB samples, MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization. Longhorn is based in Bethesda, Maryland.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005501/en/
Source: Longhorn Vaccines & Diagnostics
View this news release online at:
http://www.businesswire.com/news/home/20190919005501/en
